Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells.
暂无分享,去创建一个
D. Zaller | S. Antonenko | A. Palmieri | L. Fayadat-Dilman | M. Beaumont | M. Cancilla | P. Brandish | D. Tomazela | Prasanthi Geda | Yujie Qu | R. Garbaccio | Sanjiv J. Shah | Nick Knudsen | Anthony Manibusan | P. Miller | Shuli Zhang | I. Figueroa | D. Gately | J. Kern | L. Moy | Linda Liang | M. Zielstorff | M. Cheng | Huiping Ma | L. Benso | Guo Feng | Juhi Firdos | Laura Garvin-Queen | C. Haines | S. Hseih | D. Hodges | Kristen Kwasnjuk | J. Shin | Peter Stivers | Yingchaun Sun | Hyun Woo | Yiwei Zhang | Laurence Fayadat-Dilman | Lia Benso | Nick A. Knudsen | John S Shin | Mark Zielstorff
[1] A. Berkenblit,et al. Antibody-Drug Conjugates for Cancer Treatment. , 2018, Annual review of medicine.
[2] C. Dumontet,et al. Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.
[3] Ying Sun,et al. Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs. , 2016, Bioconjugate chemistry.
[4] C. Bertozzi,et al. Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development , 2014, Bioconjugate chemistry.
[5] J. Jacobs,et al. The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects , 2014, Arthritis Research & Therapy.
[6] Peter G Schultz,et al. A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.
[7] Peter G Schultz,et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.
[8] S. Moestrup,et al. Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] D. Goldenberg,et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. , 2004, Blood.
[10] A. Rudensky,et al. Effect of Decreasing the Affinity of the Class II-Associated Invariant Chain Peptide on the MHC Class II Peptide Repertoire in the Presence or Absence of H-2M1 , 2004, The Journal of Immunology.
[11] G. Molema,et al. Selective Intracellular Delivery of Dexamethasone into Activated Endothelial Cells Using an E-Selectin-Directed Immunoconjugate , 2002, The Journal of Immunology.
[12] Goldenberg,et al. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines , 1999, Immunology.
[13] G. Griffiths,et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. , 1996, The Biochemical journal.
[14] Damon L. Meyer,et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.